Lyell Immunopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Lyell Immunopharma, Inc. (LYEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.05% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-12
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.15%, a 0.48% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 4.13%, a 92.99% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 2.14%, a 214.71% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.68%.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.05%, a 2.88% decline from fiscal 2024.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.17%, a 0.97% increase from fiscal 2023.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.13%, a 40.96% increase from fiscal 2022.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.93%, a 266.25% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.05% 10-K · filed 2026-03-12 | |||
| 2024-12-31 | 4.17% 10-K · filed 2026-03-12 | |||
| 2024-09-30 | 4.17% 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | 4.17% 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | 4.15% 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | 4.13% 10-K · filed 2026-03-12 | |||
| 2023-09-30 | 4.13% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 4.09% 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 4.13% 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | 2.93% 10-K · filed 2025-03-11 | |||
| 2022-09-30 | 2.32% 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 2.28% 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 2.14% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 0.80% 10-K · filed 2024-02-28 | |||
| 2021-09-30 | 0.79% 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 0.76% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 0.68% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 0.79% 10-K · filed 2023-02-28 | |||
| 2020-09-30 | 0.99% 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | 1.39% 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | 1.91% 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |